Profile data is unavailable for this security.
About the company
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Company’s Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).
- Revenue in USD (TTM)870.72k
- Net income in USD-24.80m
- Incorporated2020
- Employees8.00
- LocationCyclo Therapeutics Inc6714 Nw 16Th Street, Suite BGAINESVILLE 32653United StatesUSA
- Phone+1 (386) 418-8060
- Websitehttps://www.cyclotherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Talphera Inc | 281.00k | -15.64m | 11.88m | 15.00 | -- | 1.23 | -- | 42.28 | -0.6786 | -0.6792 | 0.0118 | 0.5662 | 0.0127 | -- | -- | 18,733.33 | -70.64 | -22.60 | -82.44 | -28.55 | -- | -- | -5,565.48 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| Gelteq Ltd | 0.00 | -1.54m | 14.82m | -- | -- | 1.05 | -- | -- | -0.1611 | -0.1611 | 0.00 | 1.50 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.38 | -32.41 | 0.0605 | -- | -- | -- | -72.77 | -- | -- | -- |
| Cumberland Pharmaceuticals, Inc. | 36.79m | -10.87m | 15.17m | 91.00 | -- | 0.6107 | -- | 0.4123 | -0.7692 | -0.7692 | 2.61 | 1.77 | 0.4472 | 0.9316 | 3.07 | 404,235.70 | -13.18 | -7.03 | -20.32 | -9.52 | 83.31 | 79.95 | -29.48 | -17.64 | 0.9884 | -29.44 | 0.3967 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Bright Green Corp | 0.00 | -9.03m | 15.33m | 5.00 | -- | 1.71 | -- | -- | -0.0485 | -0.0485 | 0.00 | 0.0467 | 0.00 | -- | -- | 0.00 | -44.63 | -- | -73.32 | -- | -- | -- | -- | -- | -- | -13,031.30 | 0.0828 | -- | -- | -- | 52.54 | -- | -- | -- |
| TherapeuticsMD Inc | 1.60m | -3.97m | 15.34m | 1.00 | -- | 0.5661 | -- | 9.61 | -0.3499 | -0.291 | 0.1399 | 2.35 | 0.0355 | -- | 0.4944 | 1,596,000.00 | -8.81 | -53.35 | -11.41 | -111.61 | 31.45 | 86.67 | -248.56 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Cara Therapeutics Inc | 8.69m | -95.53m | 17.01m | 55.00 | -- | 24.05 | -- | 1.96 | -1.75 | -1.75 | 0.1589 | 0.0129 | 0.1042 | 0.6312 | 4.59 | 157,927.30 | -114.63 | -35.76 | -142.84 | -40.82 | 56.44 | -- | -1,099.76 | -162.10 | 4.71 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Marinus Pharmaceuticals Inc | 31.47m | -140.49m | 17.75m | 165.00 | -- | -- | -- | 0.5642 | -2.47 | -2.47 | 0.5524 | -1.21 | 0.238 | 0.6542 | 7.75 | 190,703.00 | -106.26 | -49.64 | -140.93 | -57.76 | 90.17 | -- | -446.49 | -518.96 | 1.47 | -10.06 | -- | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| DH Enchantment Inc | 100.00 | -173.19k | 19.54m | 1.00 | -- | -- | -- | 195,396.80 | -0.0002 | -0.0002 | 0.00 | -0.0012 | 0.0438 | 0.1493 | -- | 100.00 | -7,579.43 | -- | -- | -- | 0.00 | -- | -173,190.00 | -- | 0.0029 | -14.85 | -- | -- | -95.43 | -- | 59.53 | -- | -- | -- |
| Cyclo Therapeutics Inc | 870.72k | -24.80m | 20.06m | 8.00 | -- | -- | -- | 23.04 | -0.9232 | -0.9232 | 0.0322 | -0.4683 | 0.1605 | 0.342 | 3.54 | 108,840.00 | -457.10 | -132.22 | -- | -215.17 | 91.24 | 90.37 | -2,848.18 | -1,114.04 | 0.1614 | -- | -- | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| China Health Industries Holdings, Inc. | 95.95k | -1.36m | 21.30m | 32.00 | -- | -- | -- | 221.99 | -0.0208 | -0.0208 | 0.0015 | -0.0366 | 0.0037 | 0.5035 | 20.57 | 2,998.44 | -5.18 | 3.04 | -6.89 | 3.66 | -5.34 | 69.55 | -1,419.49 | 28.61 | 0.0377 | -- | 1.76 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
| Nexgel Inc | 6.73m | -3.53m | 22.13m | 19.00 | -- | 4.74 | -- | 3.29 | -0.5815 | -0.5815 | 1.10 | 0.6902 | 0.6558 | 3.21 | 6.56 | 354,105.30 | -37.28 | -44.61 | -51.10 | -56.19 | 31.61 | 5.02 | -56.85 | -180.98 | 0.9291 | -- | 0.2235 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| BioXcel Therapeutics Inc | 2.28m | -71.00m | 23.25m | 74.00 | -- | -- | -- | 10.21 | -2.15 | -2.15 | 0.0637 | -2.02 | 0.0305 | 1.14 | 6.17 | 30,756.76 | -95.08 | -74.57 | -168.28 | -84.06 | 10.98 | -- | -3,119.33 | -32,300.74 | 1.81 | -6.54 | 5.55 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Polypid Ltd | 0.00 | -26.86m | 23.34m | 59.00 | -- | 10.81 | -- | -- | -7.48 | -7.48 | 0.00 | 0.3172 | 0.00 | -- | -- | 0.00 | -132.55 | -76.92 | -222.42 | -89.61 | -- | -- | -- | -- | -- | -25.48 | 0.7813 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
| Natural Alternatives International, Inc. | 112.98m | -8.50m | 26.34m | 296.00 | -- | 0.3286 | -- | 0.2332 | -1.45 | -1.45 | 19.19 | 12.94 | 0.7028 | 4.35 | 8.25 | 381,679.10 | -5.29 | 2.33 | -6.04 | 2.80 | 5.30 | 14.24 | -7.53 | 2.06 | 1.50 | -9.35 | 0.1536 | 0.00 | -26.11 | -3.82 | -386.16 | -- | -10.75 | -- |
| Dare Bioscience Inc | 1.88m | -3.60m | 28.08m | 23.00 | -- | -- | -- | 14.93 | -0.5276 | -0.5276 | 0.2303 | -0.1737 | 0.0873 | -- | 2.28 | 81,796.52 | -16.72 | -109.51 | -199.47 | -246.26 | 3.50 | -- | -191.61 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
Data as of Nov 22 2024. Currency figures normalised to Cyclo Therapeutics Inc's reporting currency: US Dollar USD
5.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EPIQ Capital Group LLCas of 30 Sep 2024 | 739.43k | 2.58% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 598.69k | 2.09% |
| Geode Capital Management LLCas of 30 Sep 2024 | 152.33k | 0.53% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 79.51k | 0.28% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 39.53k | 0.14% |
| Wealth Enhancement Advisory Services LLCas of 30 Sep 2024 | 23.40k | 0.08% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 21.72k | 0.08% |
| UBS Securities LLCas of 30 Sep 2024 | 7.93k | 0.03% |
| Tower Research Capital LLCas of 30 Sep 2024 | 5.40k | 0.02% |
| UBS Financial Services, Inc.as of 30 Sep 2024 | 4.53k | 0.02% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
